
|Articles|November 14, 2008
Valeant Pharmaceuticals acquires DermaTech
Aliso Viejo, Calif. - Valeant Pharmaceuticals has announced it has acquired DermaTech, an Australian pharmaceutical company focused on dermatology products, marketwatch reports.
Advertisement
Aliso Viejo, Calif.
- Valeant Pharmaceuticals has announced it has acquired DermaTech, an Australian pharmaceutical company focused on dermatology products, for AU$19 million, marketwatch reports.
The transaction will expand Valeant’s specialty pharmaceutical portfolio through the acquisition of key products,according to the company.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
UCB Presents 3-Year BE HEARD Trial Results for Bimekizumab in Moderate-to-Severe HS
3
World Cancer Day 2026: La Roche-Posay and ONS Partner to Launch Skin of Color Toxicity Repository
4
Sagimet and Ascletis Report Positive 52-Week Safety and Efficacy Data for Denifanstat in Acne
5











